ClinicalTrials.gg
Not yet recruitingNCT07645300LODESTARUpdated Jun 12, 2026

LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

A Phase 2 interventional study of phase 2A Chlorthalidone and phase 2A Spironolactone in Hypertension Treated With Antihypertensive Drugs and Chronic Kidney Disease, 3B and 4, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development — 5 open to participants now, 7 under way, none of them phase 3. Renal Insufficiency, Chronic · VA Office of Research and Development.

Planned enrollment
7th of 21
160 · median 100
Started
2026
the only one that year
Phase 2
5 of 22
1 open now
Registered
21st of 22
by date

Among the 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development, this one is the 7th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 21st registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development, or all of them as a file.
02

Study summary

The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.

Read the detailed description

Highly prevalent among patients with chronic kidney disease (CKD) , poor blood pressure (BP) control is a modifiable risk factor for both kidney failure progression and cardiovascular (CV) disease. Although the mineralocorticoid receptor antagonist (MRA) spironolactone (SPL) is recommended to treat resistant hypertension in patients with CKD, 34% discontinue SPL within 12 weeks, mostly due to hyperkalemia. The potassium (K) binding agent patiromer reduced the discontinuation rate to 14%, but the added expense and potential drug interactions are of concern. SPL, a steroidal MRA, reduces albuminuria and rates of decline in eGFR. In type 2 diabetes and CKD, the non-steroidal MRA finerenone reduces kidney failure and CV outcomes but is not indicated for the treatment of hypertension. Due to concern of hyperkalemia, SPL is barely prescribed in these patients. In 2021, the investigators reported that chlorthalidone (CTD) in people with advanced CKD was effective in lowering BP and albuminuria by 50%. However, reversible changes in kidney function and hypokalemia were common. The investigators believe that a very low dose combination strategy of CTD + SPL will be effective in lowering BP, maintaining K, and providing target organ protection. However, the optimal dose to maintain K and lower BP remains unclear. To test this hypothesis, the investigators propose a pilot proof-of-concept study (phase 2A) followed by a larger phase 2B study. Proof of Concept, phase 2A: To test the hypothesis that low or very low dose CTD combined with SPL will improve BP, the investigators will perform a pilot, single-center, placebo-controlled, double-blind, randomized trial among patients with CKD and poorly controlled hypertension. After a two-week, patient-blind, placebo run-in, the investigators will randomize 50 hypertensive people to one of 4 groups in equal numbers: placebo; CTD very low dose; SPL very low dose QD; or a combination of CTD very low dose + SPL very low dose for 6 weeks. At 6 weeks, doses will be doubled for a further 6 weeks. The primary endpoint will be assessed by change from baseline to 6 weeks and 12 weeks in systolic AOBP and serum K for the combination group compared to placebo. If CTD + SPL is more effective than placebo, the investigators will perform the phase 2B trial. In this trial, the investigators will test the hypothesis that among patients with moderate to advanced CKD and poorly controlled hypertension, compared to add-on SPL or add-on CTD, treatment over 12 weeks with add-on combination of spironolactone (SPL) and chlorthalidone (CTD) will more effectively lower unattended systolic automated office blood pressure (uAOBP). Furthermore, combination therapy will reduce albuminuria more than either drug alone providing evidence for target organ protection. CTD will produce these effects by further reducing extracellular fluid volume in combination with SPL.

03

Conditions studied

  • Hypertension Treated With Antihypertensive Drugs
  • Chronic Kidney Disease, 3B and 4

Keywords

  • hypertension
  • chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study is limited to US Veterans
  • estimated by race-independent CKD-EPI formula \< 45 ml/min/1.73m2 but 15 mL/min/1.73m2
  • Hypertension

    • The investigators will use clinic AOBP of at least 135/85 to define hypertension
  • Treatment with antihypertensive drugs

    • This would require the use of at least one antihypertensive drug
    • One of the drugs should be either an ACE inhibitor or ARB or a beta-blocker at the time of randomization
  • Serum K 3.5 to 5.2 mEq/L at the time of randomization

Exclusion criteria

Exclusion Criteria:

  • Clinic AOBP of >=160/100 mmHg
  • Use of:

    • SPL
    • eplerenone
    • amiloride
    • triamterene
    • finerenone
    • thiazide
    • thiazide-like drugs (CTD, HCTZ, metolazone, indapamide) or the use of K binders or fludrocortisone in the previous 4 weeks
    • K supplementation would be allowed
  • Myocardial infarction, heart failure hospitalization, or stroke 8 weeks prior to randomization
  • If the patient is only on an alpha blocker, as the sole antihypertensive drug, they will be excluded
  • Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of
  • Known or a prior documented adverse reaction to CTD or SPL
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    phase 2A

    Drug: phase 2A Chlorthalidone · Drug: phase 2A Spironolactone · Drug: phase 2A Chlorthalidone + Spironolactone

  • Experimental
    Chlorthalidone

    phase 2A Chlorthalidone(CTD) very low dose (VLD) x 6 weeks

    Drug: phase 2A Chlorthalidone

  • Experimental
    Spironolactone

    phase 2A Spironolactone(SPL) very low dose (VLD) x 6 weeks

    Drug: phase 2A Spironolactone

  • Experimental
    CTD + SPL

    phase 2A Chlorthalidone(CTD) VLD + Spironolactone(SPL) VLD x 6 weeks

    Drug: phase 2A Chlorthalidone + Spironolactone

  • Active comparator
    2B CTD

    phase 2B Chlorthalidone(CTD) low dose (LD) x 12 weeks

    Drug: phase 2B Chlorthalidone LD + Spironolactone LD

  • Active comparator
    2B SPL

    phase 2B Spironolactone(SPL) low dose (LD) x 12 weeks

    Drug: phase 2B Chlorthalidone LD + Spironolactone LD

  • Experimental
    2B VLD CTD + VLD SPL

    phase 2B Chlorthalidone(CTD) VLD + Spironolactone(SPL) VLD x 12 weeks

    Drug: phase 2B Chlorthalidone LD + Spironolactone LD

  • Experimental
    2B LD CTD + LD SPL

    phase 2B Chlorthalidone(CTD) LD + Spironolactone(SPL) LD x 12 weeks

    Drug: phase 2B Chlorthalidone LD + Spironolactone LD

Interventions

  • Drugphase 2A Chlorthalidone

    very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks

  • Drugphase 2A Spironolactone

    very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks

  • Drugphase 2A Chlorthalidone + Spironolactone

    very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks

  • Drugphase 2B Chlorthalidone LD + Spironolactone LD

    compare combination LD with SPL LD at 12 weeks

06

What researchers measure

Primary outcomes

  1. Unattended systolic automated office blood pressure in phase 2A

    phase 2A: the primary endpoint will be assessed by change from baseline to 6 weeks and 12 weeks in systolic AOBP for the combination group compared to placebo.

    Time frame: 12 weeks

  2. Serum K phase 2A

    phase 2A: the primary endpoint will be assessed by change from baseline to 12 weeks in serum K for the combination group compared to placebo.

    Time frame: 12 weeks

  3. Unattended systolic automated office blood pressure in phase 2B

    phase 2B: the primary endpoint will be assessed by change from baseline to 12 weeks in systolic AOBP for the combination LD group compared to SPL.

    Time frame: 12 weeks

Secondary outcomes

  1. Mediation of BP lowering by volume markers

    The investigators will evaluate changes from baseline in the following markers: B-type natriuretic peptide (BNP), seated plasma renin activity and plasma aldosterone, and 24h urinary aldosterone. The investigators will use a mediation model to ascertain the mechanism of BP lowering whether it is via reduction of volume or blockade of the renin-angiotensin system. Each of the 4 mediation variables will be analyzed individually and then in aggregate as prespecified in the statistical analysis plan.

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2032, 65 months later.

Of 58 non-industry phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 62. This study's planned 65 months is above that.

Counting every sponsor, half of 138 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Mar 31, 2032
CompletionEst.
Jun 30, 2032
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07645300
Collaborators
Michael E. DeBakey VA Medical Center, VA Salt Lake City Health Care System
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Mar 31, 2032 (estimated)
Completion
Jun 30, 2032 (estimated)
Last update
Jun 12, 2026

Study contacts

Rajiv Agarwal, MD MBBS
Contact
rajiv.agarwal@va.gov
(317) 988-2241
Rajiv Agarwal, MD MBBS
principal investigator · Richard L. Roudebush VA Medical Center, Indianapolis, IN

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion